Vitamin D signaling and the differentiation of developing dopamine systems

Neuroscience

Volumn 333, Issue , 2016, Pages 193-203

  Pertile, Renata A N ^a   Cui, Xiaoying ^a   Eyles, Darryl W ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Queensland Centre for Mental Health Research   (Australia)

Author keywords

COMT; development; dopamine; SH SY5Y; vitamin D receptor (VDR); vitamin D,1,25(OH)2D3

Indexed keywords

3 O METHYLDOPAMINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CALCITRIOL; CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE 2 RECEPTOR; HOMOVANILLIC ACID; NEUROGENIN 2; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; VITAMIN D; VITAMIN D RECEPTOR; 1,25-DIHYDROXYVITAMIN D; 3-METHOXYTYRAMINE; AMINE OXIDASE (FLAVIN CONTAINING); BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CALCITRIOL RECEPTOR; COMT PROTEIN, HUMAN; DRD2 PROTEIN, HUMAN; MESSENGER RNA; MONOAMINE OXIDASE A, HUMAN; NERVE PROTEIN; NEUROG2 PROTEIN, HUMAN; SLC18A2 PROTEIN, HUMAN; VDR PROTEIN, HUMAN; VESICULAR MONOAMINE TRANSPORTER; VITAMIN;

ARTICLE; CELL MATURATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METABOLISM; RECEPTOR BINDING; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETICS; METABOLISM; NERVOUS SYSTEM DEVELOPMENT; PHYSIOLOGY; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CATECHOL O-METHYLTRANSFERASE; CELL LINE, TUMOR; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; MONOAMINE OXIDASE; NERVE TISSUE PROTEINS; NEUROGENESIS; PROMOTER REGIONS, GENETIC; RECEPTORS, CALCITRIOL; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS; VITAMIN D; VITAMINS;

EID: 84979882450     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2016.07.020     Document Type: Article

References (39)

1. Alves dos Santos, M.T., Smidt, M.P., En1 and Wnt signaling in midbrain dopaminergic neuronal development. Neural Dev, 6, 2011, 23.
2. Brown, J., Bianco, J.I., McGrath, J.J., Eyles, D.W., 1,25-Dihydroxyvitamin D-3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett 343 (2003), 139–143.
3. Carlsson, A., Lindqvist, M., Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol, 20, 1963, 140.
4. Cheung, Y.T., Lau, W.K., Yu, M.S., Lai, C.S., Yeung, S.C., So, K.F., Chang, R.C., Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 30 (2009), 127–135.
5. Cui, X., Pelekanos, M., Liu, P.Y., Burne, T.H., McGrath, J.J., Eyles, D.W., The vitamin D receptor in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat midbrain. Neuroscience 236 (2013), 77–87.
6. Cui, X., Pertile, R.A.N., Liu, P., Eyles, D., Vitamin D regulates tyrosine hydroxylase expression: N-cadherin a possible mediator. Neuroscience, 2015.
7. Deslauriers, J., Lefrancois, M., Larouche, A., Sarret, P., Grignon, S., Antipsychotic-induced DRD2 upregulation and its prevention by alpha-lipoic acid in SH-SY5Y neuroblastoma cells. Synapse 65 (2011), 321–331.
8. Ding, L.H., Yan, J.H., Zhu, J.H., Zhong, H.J., Lu, Q.J., Wang, Z.H., Huang, C.F., Ye, Q.N., Ligand-independent activation of estrogen receptor alpha by XBP-1. Nucleic Acids Res 31 (2003), 5266–5274.
9. Eyles, D., Feldon, J., Meyer, U., Schizophrenia: do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed developmental rodent models. Transl Psychiatry, 2, 2012, e81.
10. Eyles, D.W., Burne, T.H.J., McGrath, J.J., Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol 34 (2013), 47–64.
11. Eyles, D.W., Smith, S., Kinobe, R., Hewison, M., McGrath, J.J., Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 29 (2005), 21–30.
12. Guillot, T.S., Miller, G.W., Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol Neurobiol 39 (2009), 149–170.
13. Ham, A., Lee, S.J., Shin, J., Kim, K.H., Mar, W., Regulatory effects of costunolide on dopamine metabolism-associated genes inhibit dopamine-induced apoptosis in human dopaminergic SH-SY5Y cells. Neurosci Lett 507 (2012), 101–105.
14. Haussler, M.R., Whitfield, G.K., Haussler, C.A., Hsieh, J.C., Thompson, P.D., Selznick, S.H., Dominguez, C.E., Jurutka, P.W., The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13 (1998), 325–349.
15. Heikkinen, S., Vaisanen, S., Pehkonen, P., Seuter, S., Benes, V., Carlberg, C., Nuclear hormone 1 alpha, 25-dihydroxyvitamin D-3 elicits a genome-wide shift in the locations of VDR chromatin occupancy. Nucleic Acids Res 39 (2011), 9181–9193.
16. Horlein, A.J., Naar, A.M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., Kamel, Y., Soderstrom, M., Glass, C.K., Rosenfeld, M.G., Ligand-independent repression by the thyroid-hormone receptor-mediated by a nuclear receptor co-repressor. Nature 377 (1995), 397–404.
17. Kele, J., Simplicio, N., Ferri, A.L., Mira, H., Guillemot, F., Arenas, E., Ang, S.L., Neurogenin 2 is required for the development of ventral midbrain dopaminergic neurons. Development 133 (2006), 495–505.
18. Kesby, J.P., Cui, X., Ko, P., McGrath, J.J., Burne, T.H., Eyles, D.W., Developmental vitamin D deficiency alters dopamine turnover in neonatal rat forebrain. Neurosci Lett 461 (2009), 155–158.
19. Korecka, J.A., van Kesteren, R.E., Blaas, E., Spitzer, S.O., Kamstra, J.H., Smit, A.B., Swaab, D.F., Verhaagen, J., Bossers, K., Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One, 8, 2013, e63862.
20. Kuepper, R., Skinbjerg, M., Abi-Dargham, A., The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. Handb Exp Pharmacol, 2012, 1–26.
21. Lisse, T.S., Saini, V., Zhao, H., Luderer, H.F., Gori, F., Demay, M.B., The vitamin D receptor is required for activation of cWnt and hedgehog signaling in keratinocytes. Mol Endocrinol 28 (2014), 1698–1706.
22. Lopes, F.M., Schroder, R., da Frota, M.L. Jr., Zanotto-Filho, A., Muller, C.B., Pires, A.S., Meurer, R.T., Colpo, G.D., Gelain, D.P., Kapczinski, F., Moreira, J.C., Fernandes Mda, C., Klamt, F., Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Res. 1337 (2010), 85–94.
23. Marinescu, V.D., Kohane, I.S., Riva, A., MAPPER: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes. BMC Bioinform, 6, 2005.
24. Matkovits, T., Christakos, S., Ligand occupancy is not required for vitamin D receptor and retinoid receptor-mediated transcriptional activation. Mol Endocrinol 9 (1995), 232–242.
25. McGrath, J.J., Eyles, D.W., Pedersen, C.B., Anderson, C., Ko, P., Burne, T.H., Norgaard-Pedersen, B., Hougaard, D.M., Mortensen, P.B., Neonatal vitamin D status and risk of schizophrenia A population-based case-control study. Arch Gen Psychiatry 67 (2010), 889–894.
26. Orme, R.P., Bhangal, M.S., Fricker, R.A., Calcitriol imparts neuroprotection in vitro to midbrain dopaminergic neurons by upregulating GDNF expression. PLoS One, 8, 2013, e62040.
27. Prufer, K., Racz, A., Lin, G.C., Barsony, J., Dimerization with retinoid X receptors promotes nuclear localization and subnuclear targeting of vitamin D receptors. J Biol Chem 275 (2000), 41114–41123.
28. Saramaki, A., Banwell, C.M., Campbell, M.J., Carlberg, C., Regulation of the human p21((waf1/cip1)) gene promoter via multiple binding sites for p53 and the vitamin D-3 receptor. Nucleic Acids Res 34 (2006), 543–554.
29. Sato, Y., Buchholz, D.R., Paul, B.D., Shi, Y.B., A role of unliganded thyroid hormone receptor in postembryonic development in Xenopus laevis. Mech Dev 124 (2007), 476–488.
30. Sever, R., Glass, C.K., Signaling by nuclear receptors. Cold Spring Harbor Perspect Biol, 5, 2013.
31. Sinkkonen, L., Malinen, M., Saavalainen, K., Vaisanen, S., Carlberg, C., Regulation of the human cyclin C gene via multiple vitamin D-3-responsive regions in its promoter. Nucleic Acids Res 33 (2005), 2440–2451.
32. Skorija, K., Cox, M., Sisk, J.M., Dowd, D.R., MacDonald, P.N., Thompson, C.C., Demay, M.B., Ligand-independent actions of the vitamin D receptor maintain hair follicle homeostasis. Mol Endocrinol 19 (2005), 855–862.
33. Smidt, M.P., Burbach, J.P.H., How to make a mesodiencephalic dopaminergic neuron. Nat Rev Neurosci 8 (2007), 21–32.
34. Smith, C.L., O'Malley, B.W., Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25 (2004), 45–71.
35. Strous, R.D., Bark, N., Parsia, S.S., Volavka, J., Lachman, H.M., Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: Evidence for association with aggressive and antisocial behavior. Psychiatry Res 69 (1997), 71–77.
36. Toda, M., Abi-Dargham, A., Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 9 (2007), 329–336.
37. Tunbridge, E.M., Weinberger, D.R., Harrison, P.J., A novel protein isoform of catechol O-methyltransferase (COMT): brain expression analysis in schizophrenia and bipolar disorder and effect of Val158Met genotype. Mol Psychiatry 11 (2006), 116–117.
38. Vieira, G.C., Chockalingam, S., Melegh, Z., Greenhough, A., Malik, S., Szemes, M., Park, J.H., Kaidi, A., Zhou, L., Catchpoole, D., Morgan, R., Bates, D.O., Gabb, P.D., Malik, K., LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/beta-catenin signalling in neuroblastoma. Oncotarget 6 (2015), 40053–40067.
39. Voigt, A., Zintl, F., Effects of retinoic acid on proliferation, apoptosis, cytotoxicity, migration, and invasion of neuroblastoma cells. Med Pediatr Oncol 40 (2003), 205–213.